Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics (NQ: CLDX )

44.16 -2.09 (-4.52%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 326,194
Open 45.87
Bid (Size) 44.16 (41)
Ask (Size) 44.20 (2)
Prev. Close 46.25
Today's Range 43.82 - 46.24
52wk Range 19.85 - 48.40
Shares Outstanding 47,099,831
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Celldex Therapeutics Earnings Perspective: Return On Capital Employed
 
Via Benzinga
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
By Ernest Dela Aglanu, Benzinga 
Via News Direct
Topics Death
Exposures Death

Performance

YTD
+1.77%
+1.77%
1 Month
-0.92%
-0.92%
3 Month
+25.70%
+25.70%
6 Month
+49.39%
+49.39%
1 Year
+42.41%
+42.41%

More News

Read More
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Via TheNewswire.com
Topics Death
Exposures Death
BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Via Benzinga
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022
From Celldex Therapeutics, Inc.
Via Globe NewsWire
Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data
Via Benzinga
Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022
From Celldex Therapeutics, Inc.
Via Globe NewsWire
Celldex to Participate in Upcoming November Investor Conferences
From Celldex Therapeutics, Inc.
Via Globe NewsWire
Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via Globe NewsWire
Celldex Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Celldex's Barzolvolimab Shows Rapid, Durable Responses In Early Urticaria Study
Via Benzinga
Earnings Scheduled For February 28, 2022
Via Benzinga
Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Celldex Therapeutics: Here's What You Need To Know
Via Benzinga
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug
Via Investor's Business Daily
Why U.S. Stocks Are Trading Higher, Manufacturing Report And More
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years
Via InvestorPlace
77 Biggest Movers From Yesterday
Via Benzinga
Celldex Therapeutics: Q4 Earnings Insights
Via Benzinga
Bear Market Bets In Biotech
Via Talk Markets
The Secret To Successful Investing In Biotech
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.